First AD

Second AD

Expert Perspectives in Sequencing ADC-Based Therapies in HR+ Breast Cancer

Clinical

® Clinical Focus page includes a listing of all specialities covered across  OncLive.com, including breast cancer, lung cancer, gastrointestinal cancers, genitourinary cancers, hematologic malignancies, and gynecologic cancers. Each individual specialty page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances in both the localized and metastatic settings, and ongoing research.


Breast Cancer

ELI-22-OSD1261 - /clinical/colorectal-cancer

 Breast Cancer condition center page is a comprehensive resource for clinical news and expert insights on various types of breast cancer, including those that are triple negative, hormone receptor positive, and/or HER2 positive. This page features news articles, interviews in written and video format, and podcasts that focus on treatment advances and ongoing research in breast cancer.

OncLive Peer Exchange® 

® Peer Exchange video program comprises lively expert panel discussions feature peer-to-peer exchanges providing authoritative insights, opinions, and perspectives on important issues facing today’s health care professionals. Episodes focus on updates and insights across solid and hematologic malignancies, including breast cancer, lung cancer, gastrointestinal cancers, genitourinary cancers, gynecological cancers, and hematologic malignancies. 

Video Series

Updates in the Treatment of HR+ Breast Cancer  

Peer Exchange

A panel of experts offer perspectives in sequencing ADC-Based therapies in HR+ breast cancer. 

Expert Insights on Biomarker Testing in Early-Stage Breast Cancer

Insights from TAILORx and RxPONDER in Guiding Treatment in Early-Stage HR+ Breast Cancer

Advancements in Adjuvant Therapy in Early-Stage HR+ Breast Cancer

Expert Perspectives on Optimizing Biomarker Testing in Advanced HR+/HER2- Breast Cancer

Potential With Individual Tumor Sequencing With Bespoke Testing Methodologies and ctDNA

Updates in Treatment Approaches With CDK4/6 Inhibitors in HR+ Breast Cancer

Expert Perspectives in Navigating Treatment Strategies with CDK4/6 Inhibitors in HR+ Breast Cancer

Navigating 2L Treatment Strategies with Oral SERDs and Elasestrant

Treatment Advancements Targeting the PI3K/AKT Pathway in HR+ Breast Cancer

ADC-Based Treatment Strategies HR+Breast Cancer:Updates from DESTINY-Breast06

Looking Ahead: Expert Future Perspectives in the HR+ Breast Cancer Landscape